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Consumer-based activity trackers are used to measure and improve physical activity. How-
ever, the accuracy of these devices as clinical endpoint or coaching tool is unclear. We
investigated the use of two activity trackers as measuring and coaching tool in patients with
Chronic Obstructive Pulmonary Disease (COPD) and healthy age-matched controls.
Methods
Daily steps were measured by two consumer-based activity trackers (Fitbit Zip, worn at the
hip and Fitbit Alta, worn at the wrist) and a validated activity monitor (Dynaport Movemoni-
tor) in 28 patients with COPD and 14 healthy age-matched controls for 14 consecutive days.
To investigate the accuracy of the activity trackers as a clinical endpoint, mean step count
per patient were compared with the reference activity monitor and agreement was investi-
gated by Bland-Altman plots. To evaluate the accuracy of activity trackers as coaching tool,
day-by-day differences within patients were calculated for all three devices. Additionally,
consistency of ranking daily steps between the activity trackers and accelerometer was
investigated by Kendall correlation coefficient.
Results
As a measuring tool, the hip worn activity tracker significantly underestimates daily step
count in patients with COPD as compared to DAM (mean±SD Δ-1112±872 steps/day;
p<0.0001). This underestimation is less prominent in healthy subjects (p = 0.21). The wrist
worn activity tracker showed a non-significant overestimation of step count (p = 0.13) in
patients with COPD, and a significant overestimation of daily steps in healthy controls
(mean±SD Δ+1907±2147 steps/day; p = 0.006). As a coaching tool, both hip and wrist worn
activity tracker were able to pick up the day-by-day variability as measured by Dynaport
(consistency of ranking resp. r = 0.80; r = 0.68 in COPD).
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Conclusion
Although the accuracy of hip worn consumer-based activity trackers in patients with COPD
and wrist worn activity trackers in healthy subjects as clinical endpoints is unsatisfactory,
these devices are valid to use as a coaching tool.
Introduction
Physical inactivity has been related to health outcomes such as mortality, hospitalization risk
[1] and disease progression [2] in patients with Chronic Obstructive Pulmonary Disease
(COPD). Being physically active can provoke symptoms of dyspnea in these patients and these
unpleasant symptoms lead to avoidance of physical activity (PA) [3]. A decreased PA is already
present early in the disease [4] and PA further declines with disease progression [5]. PA can
be objectively measured by using accelerometers, which have been validated in patients with
COPD [6, 7].
Nowadays, more consumer-based activity trackers are used [8]. These devices have a lower
cost as compared to medical device classified accelerometers, are easy to use and most of them
provide direct feedback on PA levels. Depending on the device, these activity trackers can pro-
vide activity-related information such as step counts, energy expenditure, intensity of activities
and heart rate. Research on the measurement properties of previous generations of waist worn
step counters showed that the validity of these step counters was sufficient in healthy subjects,
but these waist worn step counters underestimated step count during slower walking [9, 10].
Newer generation of activity trackers (including tri-axial accelerometry) are available now but
it remains unclear whether these more advanced activity trackers could be used as a valid way
to capture physical activity endpoints in clinical trials in patients with COPD. In addition, it is
not known whether the placement of the tracker (wrist or hip worn) influences the measure-
ment properties of these trackers. Wrist worn devices might be more convenient, particularly
for direct feedback on PA.
PA promotion is included as a recommended non-pharmacological intervention for all
stages of COPD in the GOLD strategy [11]. Several strategies to improve PA have been investi-
gated in patients with COPD [12]. Coaching interventions with use of activity trackers showed
significant improvements in PA [13, 14]. By monitoring and providing (real-time) feedback to
patients, these step counters or activity trackers play a crucial role in the coaching interven-
tions [15]. A qualitative analysis showed that 76.1% of the patients involved in a tele coaching
intervention considered the step counter as the most important part of the intervention [16].
The prerequisite for using these activity trackers to coach individual patients is that they can
accurately capture the individual day-by-day changes. For coaching purposes, the device
should be capable of distinguishing more and less active days within a subject.
Finally, to accomplish long-term behavior changes with coaching, activity trackers should
be user-friendly and subjects should be willing to wear these devices over a longer period of
time. Different common placement on the body (i.e. hip or wrist) may have different validity
and acceptability.
Therefore, the aim of this study is to investigate the accuracy of two consumer-based activ-
ity trackers (i.e. Fitbit Zip, worn at the hip and Fitbit Alta, worn at the wrist) in patients with
COPD and healthy age-matched controls, 1) to measure the PA of a patient (‘accuracy as a
measuring tool’); and 2) to distinguish more and less active days at an individual level (‘validity
as a coaching tool’), as compared to a validated activity monitor (i.e. Dynaport Movemonitor).
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We hypothesize 1) that activity trackers will not be able to accurately measure daily steps in
patients with COPD, and 2) that these activity trackers are capable to distinguish more and
less active days within each patient and thus are valid to be used as a coaching tool. Finally, we
aim to provide insight in the patients’ preference.
Methods
Population and design
In the present study, 30 patients with COPD were included. Patients with a diagnosis of
COPD (confirmed by spirometry (FEV1/FVC� 0.70)), with an age above 40 years old, with a
smoking history of at least 10 pack years and no moderate or severe exacerbations within 4
weeks prior to inclusion were eligible for the present study. Patients were recruited at the Uni-
versity Hospitals Leuven (Leuven, Belgium) between August 2017 and November 2019. In
addition, we included 15 age-matched healthy controls who were in absence of any known
respiratory disease, without airflow obstruction (confirmed by spirometry) and who had no or
a marginal smoking history (< 5 pack years). For both groups, subjects were not included if
they used a walking aid in daily life or if they had an impaired gait pattern, as judged by the
investigator. The study was approved by the ethical committee of University Hospital Leuven
(s60227) and all subjects signed the informed consent prior to data collection. This observa-
tional study consisted of one clinical visit and a testing phase of 14 days. During the testing
phase, subjects were instructed to wear the activity monitor and two activity trackers simulta-
neously. At the end of the testing phase, subjects were asked to complete a questionnaire col-
lecting information about the experience of patients with wearing the activity trackers.
Clinical measurements
At the clinical visit, both groups performed the same clinical assessments: 1) an anthropomet-
ric assessment (weight and height); 2) a post-bronchodilator spirometry (according to the
ATS-ERS guidelines) retrieving FEV1 and FVC [17]; 3) functional exercise capacity measured
by the best out of two six-minute walking tests conducted in a 50 m corridor using standard-
ized encouragement [18]; 4) symptoms of dyspnea assessed by the modified Medical Research
Council (mMRC) dyspnea scale [19]; 5) clinical visit version of PROactive questionnaire,
investigating patient’ reported physical activity experience [20]; and 6) health status questioned
by the COPD Assessment Test (CAT) [21].
Physical activity monitor
Patients were provided with an activity monitor (i.e. Dynaport Movemonitor) and two con-
sumer-based activity trackers; i.e. Fitbit Alta, worn at the wrist (wrist-AT) and Fitbit Zip, worn
at the hip (hip-AT) (Fig 1). Subjects were instructed to simultaneously wear these three devices
for 14 consecutive days during waking hours, except for bathing or showering.
The Dynaport Movemonitor (DAM, McRoberts BV, The Hague, the Netherlands) is a tri-
axial accelerometer, which is validated to objectively measure PA in patients with COPD [6, 7].
This monitor is worn at the lower back and does not provide direct feedback. Battery auton-
omy of this device is 14 days. The DAM captures amount (e.g. expressed as step count) and
intensity as well as time in different postures (e.g. standing, lying, walking) and wearing time.
Physical activity trackers
The Fitbit Zip (hip-AT) (Fitbit, Inc., San Francisco, USA) is a consumer-based activity
tracker with clip system, worn at the hip, which we attached on the same strap as the DAM,
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at the position of the right hip. This device measures daily step count, walking distance and
estimates energy expenditure, based on an in-build tri-axial accelerometer and use motion
pattern algorithms. Direct feedback on these parameters and the watch function were dis-
played on the LCD screen of the device. The 3V coin battery was used, with an autonomy of
4 to 6 months.
The Fitbit Alta (wrist-AT) (Fitbit, Inc., San Francisco, USA) is a tri-axial consumer-based
activity tracker, which is worn on the wrist. The device was worn at the side preferred by the
subject. The device registers daily step count, walking distance, energy expenditure and esti-
mates time spent in moderate to intense activities, based on information from the tri-axial
accelerometer and use of motion pattern algorithms. For this observational study, only feed-
back on daily step count, the watch function and battery level were activated on the 1’4” inch
OLED display. Battery charging was necessary every 5 to 7 days and was instructed to all
subjects.
Daily step count retrieved from the DAM, hip-AT and wrist-AT and movement intensity
during walking captured by DAM were used for the present analyses. The wearing time was
only registered by the DAM. Days with a wearing time lower than 8 hours based on DAM
were excluded and only days with matching data from all three devices were used in the analy-
ses [22]. Daily step counts of the activity trackers was extracted from the online Fitbit platform
at the second clinical visit.
Participant experience
User friendliness of the hip-AT and wrist-AT was evaluated in a project-tailored question-
naire. Questions were 1) “How pleasant was it to wear this device?”; 2) “How often did you
look at the steps displayed on the activity tracker?” and 3) “How long would you like to use
this device in the future?”. All questions came with 5 answering possibilities representing a 5
point Likert scale. As final question, subjects were asked to choose which device they would
prefer to use in the future (hip worn activity tracker (e.g. Fitbit Zip), wrist worn activity tracker
(e.g. Fitbit Alta), both or none of both).
Fig 1. Positioning of the Fitbit Zip (hip), Fitbit Alta (wrist) and Dynaport Movemonitor (lower back).
https://doi.org/10.1371/journal.pone.0236676.g001
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Statistical analysis
The present study included a convenience sample of 30 patients with COPD, based on similar
studies in the field [23] and large enough to cover the whole spectrum of the disease. All statis-
tical analyses were performed using the SAS statistical package (V9.4, SAS Institute, Cary,
North Carolina, USA). All data are presented as mean ± SD, unless specified otherwise. Statis-
tical significance was set at p< 0.05 for all analyses. Patients were included in the analyses if
they had at least 3 valid days (e.g. > 8 hours of wearing time) with corresponding data with the
3 devices.
First, to investigate the accuracy of the consumer-based activity monitors in capturing PA
as a clinical trial endpoint (activity trackers as measuring tool), we 1) compared mean daily
step count per patient measured by hip-AT and wrist-AT with DAM (= reference), by use of
a paired t-test, in COPD and healthy controls separately. To test the hypothesis that the accu-
racy of the trackers relates to walking speed, we pooled the groups and tested the association
between movement intensity during walking (in quartiles) and the difference between the
trackers and the DAM using univariate linear analyses; 2) we compared mean daily step count
between COPD and healthy control using an unpaired t-test for every device separately; and 3)
we investigated the agreement of mean step count measured by the activity trackers as com-
pared to the DAM by Bland-Altman plots. These analyses were performed for patients with
COPD and healthy controls separately.
Second, to evaluate the accuracy of these activity trackers as coaching incentive for an indi-
vidual subject (activity trackers as coaching tool), we 1) calculated day-by-day differences to
the individual mean PA (for example see Fig 3 panel A). This was done for each patient for
each of the devices (DAM, hip-AT and wrist-AT). If more than 10 valid days were available,
this analysis was based on 10 randomly selected days. Else, all available valid days were used.
The day-by-day data were individually sorted based on the DAM measurement, from most
active day to least active day and corresponding days with hip-AT and wrist-AT were added to
the sorted database. Mean day-by-day differences for each day for each device were calculated
and graphically presented; and 2) the step count data retrieved from the three devices were
used to evaluate consistency of ranking between DAM and respectively hip-AT and wrist-AT.
Daily step count of the selected 10 random days were ranked from most active day to least
active day for each device separately. The ranking scores of each day for each device was com-
pared. Consistency of these rankings was evaluated by a Kendall correlation. Correlation coef-
ficient was interpreted using the following cutoffs: weak correlation r = 0.3–0.5; moderate
correlation r0.5–0.7; strong correlation r = 0.7–0.9; very strong correlation r>0.9 [24].
Finally, answers on the different questions measuring user preference were compared
between the activity trackers using chi-square analyses. Because we hypothesized that the
choice of the tracker would depend on the age of the subject [25], we calculated the proportion
of older (>65y) and younger (<65y) subjects.
Results
30 patients with COPD and 15 age-matched healthy controls wore the Dynaport Movemonitor
(DAM), Fitbit Zip (hip-AT) and Fitbit Alta (wrist-AT) for 14 consecutive days. Valid data of
the three devices could be retrieved in 28 patients with COPD (mean (SD) 11 (3) days of wear-
ing, total of 306 patient-days) and 14 healthy controls (mean (SD) 13.4 (2) days of wearing,
total of 188 patient-days), and therefore included in the present analyses. Missing data were
due to technical problems with the wrist-AT in two patients with COPD, 1 control subject had
insufficient wearing time on all days of testing. Baseline characteristics of the subjects included
in the analyses are displayed in Table 1.
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Activity trackers as a measurement tool
In the COPD group, mean step count measured by hip-AT was significantly lower (mean±SD
Δ -1112 ± 872 steps per day or -23%; p<0.0001) as compared to DAM, see Table 2. The mea-
surement by wrist-AT was not significantly different (mean±SD Δ +374 ± 1257 steps per day
or +8%; p = 0.13). In the healthy controls, the assessment by wrist-AT was significantly higher
as compared to DAM (mean±SD Δ +1907 ± 2147 steps per day or +24%; p = 0.006) with
no difference between hip-AT and DAM (mean±SD Δ -392 ± 1116 steps per day or +5%;
p = 0.21).
The underestimation of the hip-AT to DAM was related to movement intensity during
walking, with a smaller difference with higher movement intensity (p-for-trend = 0.016). The
accuracy of wrist-AT to DAM was lower with increasing movement intensity (p-for-
trend< 0.0001).
Patients with COPD were significantly less active as compared to healthy controls as mea-
sured by the three devices (mean±SD Δ 3027 ± 2790, 3746 ± 2728 and 4559 ± 3497 respectively
based on DAM, hip-AT and wrist-AT; p<0.05 for all).
The Bland-Altman analysis presented in Fig 2 (mean step count, large dots) shows a lower
mean bias for PA measured by hip-AT in healthy subjects as compared to patients with COPD
(respectively bias (95%CI) for healthy controls and COPD: -391 (-2579; 1797) steps and -1055
(-2820; 589) steps). The bias measured by wrist-AT was larger in healthy controls as compared
to patients with COPD (respectively bias (95%CI) for healthy and COPD: 1891 (-2286; 6068)
steps and 306 (-2068; 2680) steps).
Table 1. Characteristics of all subjects in the analyses, expressed as mean ± standard deviation, except◆median
[Q1–3].
COPD patients (N = 28) Healthy controls (N = 14) p-value
Age (years) 66 ± 8 69 ± 7 0.15
Gender (% male) 61 64 0.72
BMI (kg/m2) 25 ± 4 27 ± 3 0.05
FEV1 (% pred) 47 ± 18 122 ± 14 <0.0001
6MWD (m) 454 ± 109 660 ± 83 <0.0001
6MWD (% pred) 72 ± 15 109 ± 10 <0.0001
CAT (score)� 19 ± 6 (6 ± 5) <0.0001
mMRC (score)◆ 2 [1–3] 0 [0–0] <0.0001
C-PPAC (score)� 61 ± 11 (88 ± 6) <0.0001
�CAT and PROactive score only indicative in healthy controls because questionnaire is only validated for use in
patients with COPD. P-value based on unpaired t-test or Chi Square. BMI = body mass index; 6MWD = 6-minute
walking distance [26]; CAT score = COPD Assessment Test; mMRC = modified Medical Research Council Dysnea
Scale (0–4); C-PPAC = clinical visit version PROactive questionnaire—total score (0–100), with higher score
indicating better physical activity experience.
https://doi.org/10.1371/journal.pone.0236676.t001
Table 2. Average step count in patients with COPD and healthy controls. P-value compares average steps measured by Dynaport Movemonitor (DAM) to respectively
Fitbit Zip (hip-AT) and Fitbit Alta (wrist-AT), using paired t-test.
DAM hip-AT wrist-AT
Average daily step count COPD (mean ± SD) 4785 ± 2560 3673 ± 2332 5158 ± 3020
p-value compared to DAM (COPD) p < 0.0001 p = 0.13
Average daily step count healthy controls (mean ± SD) 7811 ± 3215 7419 ± 3406 9718 ± 4324
p-value compared to DAM (healthy) p = 0.21 p = 0.006
https://doi.org/10.1371/journal.pone.0236676.t002
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Activity trackers as a coaching tool
Fig 3 shows the day-by-day variability expressed as mean day-by-day differences measured by
the three devices. Difference to the individual mean PA followed the same pattern measured by
DAM, wrist-AT and hip-AT. Both activity trackers have the ability to detect patterns of more and
less active days similarly to the DAM, both in COPD (panel C) and healthy controls (panel D).
Finally, consistency of ranking from most active to less active days showed a moderate to
strong correlation in the COPD group for both hip-AT and wrist-AT (Kendall correlation
respectively 0.80 and 0.68). In the healthy controls, correlation for hip-AT and wrist-AT were
respectively 0.71 and 0.61, see Fig 4.
User preferences
54% of the COPD patients preferred the wrist worn device; a majority (69%) of these subjects
preferring wrist-AT were younger than 65 years old. 42% of the COPD group preferred the
Fig 2. Bland-Altman plots with mean and 95%CI for hip-AT and wrist-AT compared to DAM. (A, B) patients with COPD; (C,D) healthy controls; Large
symbols represent the average individual step count per subject in the study (N = 28 for COPD and N = 14 for healthy controls). Small dots represent the daily
physical activity expressed as steps per day. Mean and 95%CI are calculated based on average step count data. Hip-AT = Fitbit Zip; wrist-AT = Fitbit Alta;
DAM = Dynaport Movemonitor.
https://doi.org/10.1371/journal.pone.0236676.g002
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hip worn device, which were mostly older patients (70% of the subjects preferring the hip
worn device were older than 65 years). One patient preferred none of both devices. In healthy
subjects, 50% of the healthy subjects preferred wrist-AT, whereas 21% preferred hip-AT. Two
subjects chose both devices. Preferences in healthy controls were not related to age.
Detailed information on the user experience is displayed in Table 3. The majority of sub-
jects in both the COPD group and control group scored the activity trackers as pleasant or
very pleasant. Only a minority of subjects in the COPD group scored the hip-AT and wrist-AT
as unpleasant.
Fig 3. Graphical representation of day-by-day variability in PA, expressed as steps per day around the individual mean PA. Panel A: day-by-day differences
around the mean step count of one random patient, recorded by hip-AT, wrist-AT and DAM. Horizontal dotted line represents the mean step count, positive
numbers representing more active days as compared to the mean PA measured, negative numbers presenting less active days as compared to the mean PA. Panel
B: Individual data (1 random patient) of panel A were ranked from the most active day to the least active day according to DAM. Corresponding data of hip-AT
and wrist-AT were added. Finally, after ranking the data for every individual subject, mean (±SD) were calculated for the COPD group and healthy control group.
Pooled data are represented in panel C (COPD group) and panel D (control group). Hip-AT = Fitbit Zip; wrist-AT = Fitbit Alta; DAM = Dynaport Movemonitor.
https://doi.org/10.1371/journal.pone.0236676.g003
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Subjects in the COPD group reported that they looked more often to the wrist-AT as com-
pared to the hip-AT (hip-AT vs wrist-AT: p = 0.02; p = 0.65 respectively in COPD and con-
trols). Small differences in favor of wrist-AT could be observed for future use, however no
significant differences between hip-AT and wrist-AT could be found for future use and pleas-
antness in the COPD and control group.
Discussion
The present paper shows that 1) to capture physical activity as clinical trial endpoint, the hip
worn activity tracker (hip-AT, Fitbit Zip) significantly underestimates daily step count in
patients with COPD. This underestimation is less prominent in healthy subjects. The wrist
worn activity tracker (wrist-AT, Fitbit Alta) showed a non-significant overestimation of step
count in patients with COPD, and a significant overestimation of daily steps in healthy age-
matched controls; 2) as a coaching tool, both the hip and wrist worn activity tracker were able
Fig 4. Ranking of daily step count by DAM compared to ranking by activity trackers. DAM compared to hip-AT in COPD (panel A) and healthy
controls (panel C) and compared to ranking by wrist-AT, in COPD (panel B) and healthy controls (panel D). The larger the dot, the larger number of
subjects for the given combination of ranks, r = Kendall correlation for consistency of ranking. Hip-AT = Fitbit Zip; wrist-AT = Fitbit Alta;
DAM = Dynaport Movemonitor.
https://doi.org/10.1371/journal.pone.0236676.g004
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to pick up the day-by-day variability as measured by DAM. Additionally, a good consistency
of ranking of days was found for both the hip and wrist worn activity monitor compared to
DAM in patients with COPD; 3) finally, overall preference was fairly similar for both devices,
although an age difference could be observed in patients with COPD (e.g. higher proportion of
younger subjects preferred the wrist worn device, higher proportion of older subjects preferred
the hip worn device).
Comparison with other studies
According to Tudor-Locke et al., less than 10% error in the physical activity measure is accept-
able for activity trackers in free-living conditions [27]. Based on these criteria, step count
recorded by hip worn devices in healthy subjects and wrist worn devices in COPD subjects
would be acceptable to measure PA. However, we believe that caution is warranted when
using these activity trackers as measurement tool or physical activity endpoint for trials. The
significant underestimation of step counts in patients with COPD could be explained by the
decreased walking speed of this group, based on the lower 6MWD in patients as compared to
the healthy controls. Previous studies investigated the influence of walking speed on accuracy
of hip-worn activity trackers in laboratory settings. They showed a significant underestimation
ranging from 23% to 67% error in waist-worn devices at slower walking speeds in controlled
settings [9, 10, 28]. Indeed, our results showed a significant association between movement
intensity during walking and the accuracy of the hip trackers using free-living data (i.e. higher
underestimation with lower movement intensity).
A recent systematic review on the accuracy of Fitbit devices endorses our findings that
activity trackers tend to overestimate daily step count during free-living circumstances
in healthy subjects [23]. In our group, this overestimation of wrist-worn devices was signifi-
cantly larger in healthy subjects as compared to patients with COPD. This could possibly be
explained by the smaller spectrum of daily life activities in patients with COPD. This pattern
can also be seen in the Bland Altman plot, showing a larger difference in patients doing more
activity, and the significant negative association between movement intensity during walking
and accuracy. We hypothesize that wrist-worn activity trackers incorrectly classify non-walk-
ing activities more easily as step-like movements. As patients with COPD perform less daily
life activities (average step count for respectively healthy and COPD: 7811 ± 3215 steps/day vs
4785 ± 2560 steps/day), the error percentage is smaller as compared to healthy individuals.
However, with the current data we can only speculate on the mechanism explaining the
Table 3. User experience, expressed as percentage, based on project-tailored questionnaire for the hip worn activity tracker (hip-AT) and wrist worn activity track-
ers (wrist-AT) in COPD and control group.
COPD Control
Hip-AT Wrist-AT Hip-AT Wrist-AT
How pleasant was it to wear the tracker? Very pleasant / pleasant (%) 40 54 57 57
Neutral (%) 46 25 43 43
Not pleasant (%) 14 21 0 0
How often did you look at the steps on the tracker? Few times per day / once a day (%) 61 82 58 79
Sometimes, not daily (%) 14 7 14 14
Once / twice a week (%) 4 0 7 7
Never (%) 21 11 21 0
How long would you like to wear the tracker in the future? Few months / more than 1 year (%) 21 40 32 58
Few days / few weeks (%) 58 42 53 21
Never again (%) 21 18 15 21
https://doi.org/10.1371/journal.pone.0236676.t003
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differences in step count between both groups. Real-time minute-by-minute step count data is
necessary to confirm this suggestion. Floegel et al. showed an underestimation of step count by
wrist worn devices in older subjects using a cane or walker [28]. In the current study, we
excluded subjects with walking aids or abnormal gait pattern but it can be advised to use hip
worn devices in patients who use walking aids.
Lower cost and widespread availability of consumer-based activity trackers can make these
devices attractive options to use in different settings. However, other points of attention when
considering the use of step counters as an outcome measure, that are outside our current
research question, are first that the outcome is limited to the number of steps per day. This
omits movement intensity as an important feature of physical activity. Second, wearing time is
generally not provided with activity trackers. In our study, we only used days with sufficient
wearing time with the gold standard, but most step counters (including Fitbit products) and
smartphone applications do not report wearing time. Nevertheless, this is important to con-
sider in studies of effectiveness [22].
To the best of our knowledge, the accuracy of these activity trackers as coaching tool in
patients with COPD has not been investigated before. We believe that with the present statisti-
cal approach, we prove that activity trackers provide the information required in a coaching
intervention (e.g. distinguishing more from less active days in an individual subject) in a prac-
tical way and that they can be used in physical activity coaching interventions. The use of hip
worn physical activity trackers has shown to be effective to improve physical activity in previ-
ous coaching trials [16, 29]. Subjects in coaching interventions should be instructed to wear
the device during waking hours. As indicated before, unfortunately quality of wearing time is
not possible with most of the devices.
User preferences in our cohort concur with previous research in an Australian healthy pop-
ulation, which revealed slightly higher proportion of preference towards wrist worn devices
[25]. We found that older patients with COPD (> 65 years) had a higher preference for hip
worn device, whereas younger patients with COPD (< 65 years) preferred a wrist worn device
more. When aiming for long-term behavior change and using these activity trackers as coach-
ing tool, preference of the user should be taken into account to optimize long-term compliance.
Such interventions should allow user preference in the coaching device of choice. We found
that a small proportion of the subjects (1 patient with COPD and 2 healthy subjects) preferred
none of both devices. We need to keep in mind that these activity trackers are not ‘one fits all
solutions’ and that other interventions independent of such activity tracker are necessary.
Strengths & limitations
By using these specific statistical approaches, we were able to identify day-by-day variability of
the different devices and compare the consistency of ranking more to less active days by the
different devices. With this approach, we showed that activity trackers can be used as a coach-
ing tool. By comparing activity monitoring in both a chronic diseased population and healthy
age-matched subjects and capturing data in free-living conditions, we attempted to provide
evidence across a wide range of daily life physical activity behavior.
Although our research provided unique insights in the accuracy of activity trackers as mea-
suring and coaching tool, the following limitations should be taking into account. In this
study, Dynaport MoveMonitor (DAM) served as a criterion standard, allowing the investiga-
tion of the activity trackers in free-living conditions. Although the activity monitor (DAM) is
valid to measure PA in patients with COPD, there might still be a slight deviation from video
recording or manual step counting by a researcher. Due to the free-living setting, the use of
these gold standard methods were not possible. Finally, one should be cautious with
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extrapolating the present findings to all consumer-based activity trackers. However, as our
results are in line with previous studies using different activity trackers [9, 23, 28], it is likely to
find similar results with other consumer-based activity trackers.
Conclusion
Our research confirms that popular activity trackers (Fitbit) lack the accuracy to capture physi-
cal activity endpoints in clinical trials, especially hip worn devices in a slow walking population
and wrist worn devices in a more active population. To measure physical activity, using more
sophisticated and properly validated monitors are required.
Nevertheless, the present study provides new evidence on the validity of consumer-based
activity trackers as coaching tool. Our results confirm that these activity trackers are valid to
use as a coaching tool in both healthy and chronic diseased subjects.
Acknowledgments
The authors would like to thank I. Coosemans, V. Barbier, N. Vandenberghe, L. Claes, N.
Cooremans and K. Abts for the help with recruitment and all participants for contribution in
the study.
Author Contributions
Conceptualization: Heleen Demeyer, Thierry Troosters.
Data curation: Astrid Blondeel.
Formal analysis: Astrid Blondeel, Heleen Demeyer, Thierry Troosters.
Funding acquisition: Wim Janssens, Thierry Troosters.
Investigation: Astrid Blondeel, Heleen Demeyer.
Methodology: Heleen Demeyer, Thierry Troosters.
Project administration: Astrid Blondeel.
Resources: Wim Janssens, Thierry Troosters.
Supervision: Thierry Troosters.
Writing – original draft: Astrid Blondeel.
Writing – review & editing: Heleen Demeyer, Wim Janssens, Thierry Troosters.
References
1. Gimeno-Santos E, Frei A, Steurer-Stey C, de Batlle J, Rabinovich RA, Raste Y, et al. Determinants and
outcomes of physical activity in patients with COPD: a systematic review. Thorax. 2014; 69(8):731–9.
Epub 2014/02/22. https://doi.org/10.1136/thoraxjnl-2013-204763 PMID: 24558112
2. Demeyer H, Donaire-Gonzalez D, Gimeno-Santos E, Ramon MA, J DEB, Benet M, et al. Physical Activ-
ity Is Associated with Attenuated Disease Progression in Chronic Obstructive Pulmonary Disease. Med
Sci Sports Exerc. 2019; 51(5):833–40. Epub 2018/12/12. https://doi.org/10.1249/MSS.
0000000000001859 PMID: 30531289.
3. Ramon MA, Ter Riet G, Carsin AE, Gimeno-Santos E, Agusti A, Anto JM, et al. The dyspnoea-inactivity
vicious circle in COPD: development and external validation of a conceptual model. Eur Respir J. 2018;
52(3). Epub 2018/08/04. https://doi.org/10.1183/13993003.00079-2018 PMID: 30072504.
4. Van Remoortel H, Hornikx M, Demeyer H, Langer D, Burtin C, Decramer M, et al. Daily physical activity
in subjects with newly diagnosed COPD. Thorax. 2013; 68(10):962–3. Epub 2013/04/23. https://doi.
org/10.1136/thoraxjnl-2013-203534 PMID: 23604460
PLOS ONE Accuracy of consumer-based activity trackers as measuring tool and coaching device
PLOS ONE | https://doi.org/10.1371/journal.pone.0236676 August 4, 2020 12 / 14
5. Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, et al. Disease Progression and
Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit
Care Med. 2015; 192(3):295–306. Epub 2015/05/29. https://doi.org/10.1164/rccm.201501-0081OC
PMID: 26020495.
6. Van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D, et al. Validity of six activity
monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS
One. 2012; 7(6):e39198. Epub 2012/06/30. https://doi.org/10.1371/journal.pone.0039198 PMID:
22745715
7. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel H, Giavedoni S, et al. Validity of physical
activity monitors during daily life in patients with COPD. Eur Respir J. 2013; 42(5):1205–15. Epub 2013/
02/12. https://doi.org/10.1183/09031936.00134312 PMID: 23397303.
8. Imec Digimeter 2018 [Accessed 3 March 2020]. https://www.imec-int.com/en/digimeter2018/imec-
digimeter-2018-download.
9. Turner LJ, Houchen L, Williams J, Singh SJ. Reliability of pedometers to measure step counts in
patients with chronic respiratory disease. J Cardiopulm Rehabil Prev. 2012; 32(5):284–91. Epub 2012/
07/13. https://doi.org/10.1097/HCR.0b013e31825c49f2 PMID: 22785145.
10. Furlanetto KC, Bisca GW, Oldemberg N, Sant’anna TJ, Morakami FK, Camillo CA, et al. Step counting
and energy expenditure estimation in patients with chronic obstructive pulmonary disease and healthy
elderly: accuracy of 2 motion sensors. Arch Phys Med Rehabil. 2010; 91(2):261–7. Epub 2010/02/18.
https://doi.org/10.1016/j.apmr.2009.10.024 PMID: 20159131.
11. From the Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for
Chronic Obstructive Lung Disease (GOLD) 2018 report. 2018.
12. Troosters T, Blondeel A, Rodrigues FM, Janssens W, Demeyer H. Strategies to Increase Physical
Activity in Chronic Respiratory Diseases. Clin Chest Med. 2019; 40(2):397–404. Epub 2019/05/13.
https://doi.org/10.1016/j.ccm.2019.02.017 PMID: 31078217.
13. Mantoani LC, Rubio N, McKinstry B, MacNee W, Rabinovich RA. Interventions to modify physical activ-
ity in patients with COPD: a systematic review. Eur Respir J. 2016; 48(1):69–81. Epub 2016/04/23.
https://doi.org/10.1183/13993003.01744-2015 PMID: 27103381.
14. Demeyer H, Louvaris Z, Frei A, Rabinovich RA, de Jong C, Gimeno-Santos E, et al. Physical activity is
increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre
randomised controlled trial. Thorax. 2017; 72(5):415–23. Epub 2017/02/01. https://doi.org/10.1136/
thoraxjnl-2016-209026 PMID: 28137918
15. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change
technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus
for the reporting of behavior change interventions. Ann Behav Med. 2013; 46(1):81–95. Epub 2013/03/
21. https://doi.org/10.1007/s12160-013-9486-6 PMID: 23512568.
16. Loeckx M, Rabinovich RA, Demeyer H, Louvaris Z, Tanner R, Rubio N, et al. Smartphone-Based Physi-
cal Activity Telecoaching in Chronic Obstructive Pulmonary Disease: Mixed-Methods Study on Patient
Experiences and Lessons for Implementation. JMIR Mhealth Uhealth. 2018; 6(12):e200. Epub 2018/
12/24. https://doi.org/10.2196/mhealth.9774 PMID: 30578215
17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for
spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40
(6):1324–43. Epub 2012/06/30. https://doi.org/10.1183/09031936.00080312 PMID: 22743675
18. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory
Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease.
Eur Respir J. 2014; 44(6):1428–46. Epub 2014/11/02. https://doi.org/10.1183/09031936.00150314
PMID: 25359355.
19. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical
Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive
pulmonary disease. Thorax. 1999; 54(7):581–6. Epub 1999/06/22. https://doi.org/10.1136/thx.54.7.581
PMID: 10377201
20. Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, et al. The PROactive
instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur
Respir J. 2015; 46(4):988–1000. Epub 2015/05/30. https://doi.org/10.1183/09031936.00183014 PMID:
26022965
21. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of
the COPD Assessment Test. Eur Respir J. 2009; 34(3):648–54. Epub 2009/09/02. https://doi.org/10.
1183/09031936.00102509 PMID: 19720809.
22. Demeyer H, Burtin C, Van Remoortel H, Hornikx M, Langer D, Decramer M, et al. Standardizing the
analysis of physical activity in patients with COPD following a pulmonary rehabilitation program.
PLOS ONE Accuracy of consumer-based activity trackers as measuring tool and coaching device
PLOS ONE | https://doi.org/10.1371/journal.pone.0236676 August 4, 2020 13 / 14
Chest. 2014; 146(2):318–27. Epub 2014/03/08. https://doi.org/10.1378/chest.13-1968 PMID:
24603844
23. Feehan LM, Geldman J, Sayre EC, Park C, Ezzat AM, Yoo JY, et al. Accuracy of Fitbit Devices: Sys-
tematic Review and Narrative Syntheses of Quantitative Data. JMIR Mhealth Uhealth. 2018; 6(8):
e10527. Epub 2018/08/11. https://doi.org/10.2196/10527 PMID: 30093371
24. Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research.
Malawi Med J. 2012; 24(3):69–71. Epub 2013/05/03. PMID: 23638278
25. Alley S, Schoeppe S, Guertler D, Jennings C, Duncan MJ, Vandelanotte C. Interest and preferences for
using advanced physical activity tracking devices: results of a national cross-sectional survey. BMJ
Open. 2016; 6(7):e011243. Epub 2016/07/09. https://doi.org/10.1136/bmjopen-2016-011243 PMID:
27388359
26. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur
Respir J. 1999; 14(2):270–4. Epub 1999/10/09. https://doi.org/10.1034/j.1399-3003.1999.14b06.x
PMID: 10515400.
27. Tudor-Locke C, Sisson SB, Lee SM, Craig CL, Plotnikoff RC, Bauman A. Evaluation of quality of com-
mercial pedometers. Can J Public Health. 2006; 97 Suppl 1:S10-5, S-6. Epub 2006/05/09. https://doi.
org/10.1007/BF03405359 PMID: 16676833.
28. Floegel TA, Florez-Pregonero A, Hekler EB, Buman MP. Validation of Consumer-Based Hip and Wrist
Activity Monitors in Older Adults With Varied Ambulatory Abilities. The journals of gerontology Series A,
Biological sciences and medical sciences. 2017; 72(2):229–36. Epub 2016/06/04. https://doi.org/10.
1093/gerona/glw098 PMID: 27257217
29. Mendoza L, Horta P, Espinoza J, Aguilera M, Balmaceda N, Castro A, et al. Pedometers to enhance
physical activity in COPD: a randomised controlled trial. Eur Respir J. 2015; 45(2):347–54. Epub 2014/
09/28. https://doi.org/10.1183/09031936.00084514 PMID: 25261324
PLOS ONE Accuracy of consumer-based activity trackers as measuring tool and coaching device
PLOS ONE | https://doi.org/10.1371/journal.pone.0236676 August 4, 2020 14 / 14
